Physician profile
Drew Jorgensen
NPI 1356787790
$1,439.82
in general payments reported to CMS, 2019-2025
11 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $40.79 · 2023: $488 · 2024: $235 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $864.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $356.94 | 2019-2025 | Ultomiris |
| Ucb, INC. | $356.33 | 2023-2024 | Briviact, Fintepla |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $180.15 | 2019-2020 | |
| Microvention, INC. | $147.50 | 2023 | Web Aneurysm Embolization System, Stent |
| Abbott Laboratories | $134.60 | 2019-2023 | Infinity |
| Astrazeneca Pharmaceuticals LP | $69.28 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.58 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $41.98 | 2019 | |
| Abbvie INC. | $34.82 | 2025 | |
| Janssen Pharmaceuticals, INC | $30.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Jorgensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.